Entrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells $15,416.61 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDAGet Rating) CEO Dipal Doshi sold 1,023 shares of Entrada Therapeutics stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $15.07, for a total value of $15,416.61. Following the transaction, the chief executive officer now owns 215,422 shares of the company’s stock, valued at approximately $3,246,409.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Dipal Doshi also recently made the following trade(s):

  • On Wednesday, September 21st, Dipal Doshi sold 3,402 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.12, for a total value of $51,438.24.
  • On Thursday, September 15th, Dipal Doshi sold 200 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.04, for a total value of $3,008.00.
  • On Thursday, September 8th, Dipal Doshi sold 1,100 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.16, for a total value of $16,676.00.
  • On Wednesday, August 31st, Dipal Doshi sold 171 shares of Entrada Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $2,052.00.
  • On Monday, August 29th, Dipal Doshi sold 1,639 shares of Entrada Therapeutics stock. The stock was sold at an average price of $12.88, for a total value of $21,110.32.
  • On Wednesday, July 27th, Dipal Doshi sold 2,000 shares of Entrada Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $24,000.00.
  • On Monday, June 27th, Dipal Doshi sold 4,000 shares of Entrada Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $48,000.00.

Entrada Therapeutics Stock Up 12.4 %

Entrada Therapeutics stock traded up $1.66 during trading on Friday, hitting $15.09. The stock had a trading volume of 38,563 shares, compared to its average volume of 91,097. Entrada Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $36.85. The stock’s 50 day moving average is $12.63 and its two-hundred day moving average is $9.90. The stock has a market cap of $473.34 million and a price-to-earnings ratio of -1.25.

Entrada Therapeutics (NASDAQ:TRDAGet Rating) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.74) EPS for the quarter.

Institutional Investors Weigh In On Entrada Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TRDA. New York State Common Retirement Fund bought a new stake in Entrada Therapeutics during the 1st quarter valued at $46,000. Bank of New York Mellon Corp raised its holdings in Entrada Therapeutics by 60.6% during the 1st quarter. Bank of New York Mellon Corp now owns 21,933 shares of the company’s stock valued at $206,000 after acquiring an additional 8,276 shares during the period. Ghisallo Capital Management LLC bought a new stake in Entrada Therapeutics during the 4th quarter valued at $257,000. Walleye Capital LLC bought a new stake in Entrada Therapeutics during the 1st quarter valued at $419,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Entrada Therapeutics by 7.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 68,704 shares of the company’s stock valued at $646,000 after acquiring an additional 4,685 shares during the period. Institutional investors own 79.02% of the company’s stock.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upped their price objective on Entrada Therapeutics from $10.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday, August 16th.

About Entrada Therapeutics

(Get Rating)

Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.

Featured Stories

Insider Buying and Selling by Quarter for Entrada Therapeutics (NASDAQ:TRDA)

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.